Organon & Co.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Joseph T. Morrissey Jr.
- Full Time Employees
- 10,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 30 Hudson Street Jersey City NJ United States of America 07302
- IPO Date
- May 14, 2021
- CIK
- 0001821825
- Website
- organon.com
- Similar Companies
- Business
- Organon & Co. is a global pharmaceutical company specializing in developing and delivering health solutions across women's health, biosimilars, and established brands. The company offers a portfolio with more than 70 medicines and devices covering therapeutic areas such as reproductive health (contraception, fertility, maternal health, vaginal health), cardiovascular disease, neurology, dermatology, autoimmune and respiratory conditions. Key products include contraceptives like Nexplanon, hormone replacement therapies, biosimilar medicines, and established brands addressing allergies, dermatology, bone health, and non-opioid pain management. Organon operates internationally, with commercial presence in over 140 markets, including major operations in the United States, Europe, Canada, Japan, and Asia Pacific. It maintains six manufacturing sites in Belgium, Brazil, Indonesia, Mexico, the Netherlands, and the United Kingdom. Founded in 2021 as a spin-off from Merck & Co., Organon transitioned into an independent publicly traded company headquartered in Jersey City, New Jersey. Recent strategic developments include the acquisition of Forendo Pharma in late 2021 to expand its portfolio with innovative women's health therapies, and the launch of new products such as Emgality and Vtama contributing to established brand growth. In 2024, Organon reported revenue growth driven by portfolio expansion and market penetration, alongside disciplined cost management and efficiency programs targeting $200 million operating savings in 2025. The company emphasizes advancing women's health globally through continuous innovation and targeted therapeutic focus, while adapting to market exclusivity changes and enhancing its biosimilar and established medicine franchises. Organon's main industry segments include pharmaceuticals focused on reproductive medicine, hormone therapies, biosimilars, and established health brands, serving healthcare systems, providers, and patients worldwide. The company's business model integrates product development, manufacturing, and commercialization across diverse geographic regions, leveraging innovative drug-device combinations and broad therapeutic expertise to address unmet medical needs in women's health and beyond. This comprehensive product portfolio and recent strategic investments position Organon as a dedicated health care company aiming to improve patient outcomes through targeted therapies and global market expansion.
Company News
Is Trending Stock Organon & Co. (OGN) a Buy Now?
VIRGINIA RETIREMENT SYSTEMS ET Al Makes New $770,000 Investment in Organon & Co. $OGN
Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device
Orogen Royalties Acquires the Serpent Gold Project in Nevada
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Orogen Royalties Acquires Two Gold Projects in Southwest Utah
Bank of America Corp DE Has $4.42 Million Stock Position in Organon & Co. $OGN
National Can-RISE Study to Help Close Critical Gaps in Menopause Research
Organon & Co. (NYSE:OGN) Sets New 52-Week High – Still a Buy?
Orogen Royalties Acquires a Royalty on the Haldane Silver Project
Orogen Royalties and Aurum Discovery form Generative Alliance in Norway
Organon & Co. $OGN Shares Purchased by California State Teachers Retirement System
Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability
Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability
Compared to Estimates, Organon (OGN) Q2 Earnings: A Look at Key Metrics
Organon (OGN) Lags Q2 Earnings Estimates
Organon Announces Quarterly Dividend
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Orogen Royalties Announces Project, Partner and Royalty Update
New Analysis of Phase 3 Pooled Data for Organon's VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1